ViewPoint raises $4M in series A

ViewPoint Therapeutics Inc. (San Francisco, Calif.) raised $4 million in a series A round co-led by Mission Bay Capital and Lagunita BioSciences. Biotechnology Value Fund, the University of Michigan MINTS initiative, Asset Management Ventures and individual investors also participated.

Housed in the San Francisco JLABS hub of Johnson & Johnson (NYSE:JNJ), ViewPoint is developing therapeutics that target misfolded proteins to prevent or treat cataracts. CSO Leah Makley declined to say when preclinical lead program VP1-001, a small molecule stabilizer of alpha-crystallin, would enter the clinic (see BioCentury Innovations, Nov. 12, 2015). ...